What Is Ebglyss and How Is It Administered?
Ebglyss (lebrikizumab-lbkz) is an injectable biologic medication approved by the FDA in 2023 for moderate-to-severe atopic dermatitis in adults and children 12 years and older. It is given as a subcutaneous injection, typically every two weeks after initial doses.[1]
How Often Do Patients Inject Ebglyss?
Treatment starts with two loading doses four weeks apart, followed by maintenance injections every two weeks. A pre-filled syringe or autoinjector is used at home after training.[1]
Why an Injectable Instead of a Pill?
Ebglyss targets IL-13, a protein driving inflammation in eczema. As a monoclonal antibody, it requires injection because oral pills can't deliver large proteins intact through digestion.[1]
How Does Ebglyss Compare to Oral Eczema Treatments?
Unlike injectables like Dupixent (dupilumab), oral options such as Rinvoq (upadacitinib) or Cibinqo (abrocitinib) are JAK inhibitors taken as daily pills but carry black-box warnings for serious infections, clots, and cancer risks. Ebglyss avoids systemic immunosuppression.[1][2]
Common Patient Questions on Ebglyss Delivery
- Injection site reactions? Redness, swelling, or pain occur in about 3-5% of patients, usually mild.[1]
- Storage? Refrigerate at 36-46°F; allow to warm to room temperature before injecting.[1]
- Missed dose? Inject as soon as possible, then resume schedule.[1]
[1]: FDA Prescribing Information for Ebglyss (lebrikizumab-lbkz), https://www.accessdata.fda.gov/drugsatfdadocs/label/2023/761345s000lbl.pdf
[2]: FDA Prescribing Information for Rinvoq, https://www.accessdata.fda.gov/drugsatfdadocs/label/2021/211675s000lbl.pdf